What to Know About Colgate-Palmolive Director John Cahill Selling 4,170 Shares for $389,353
Key Points
Cahill executed a sale of 4,170 shares on Aug. 6, 2026, realizing ~$389,353 in transaction value.
The disposition reduced his total equity holdings by 6%, including shares acquired via option exercise, and 13% of his direct ownership.
The transaction involved the exercise of 4,170 stock options at $71.56 per share, while 36,357 shares remain held indirectly by a trust.
Following the trade, the director maintains a total equity position valued at $6.02 million as of the Aug. 6, 2026, market close.
- 10 stocks we like better than Colgate-Palmolive ›
John T. Cahill, Director of Colgate-Palmolive Company (NYSE:CL), reported a sale of 4,170 shares of Common Stock on Aug. 6, 2026, as disclosed in an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$389,353 |
| Shares sold | 4,170 |
| Post-transaction shares (directly held) | 28,373 |
| Post-transaction shares (indirectly held) | 36,357 |
| Post-transaction value | $6.02 million |
Transaction value based on SEC Form 4 weighted average sale price ($93.37); post-transaction value based on Aug. 6, 2026, market close ($93.00).
Key questions
- What was the structural context of this disposal?
The transaction was an exercise and sale of stock options awarded in May 2019 that became exercisable in annual installments, representing a routine realization of long-term incentive compensation. - How is the insider's remaining equity structured?
Following the sale of 4,170 shares, the director's equity is split between 28,373 shares held directly and 36,357 shares held indirectly by a trust, maintaining a multi-layered ownership structure. - What does the timing of the sale indicate regarding valuation?
The sale was executed at $93.37 per share, slightly above the market close of $93.00 on the transaction date, and occurred as the stock had produced a 10% total return over the preceding 12 months as of Aug. 6, 2026.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-06) | $93.00 |
| Market Capitalization | $74.6 billion |
| Revenue (TTM) | $21.0 billion |
| Net Income (TTM) | $2.0 billion |
Company Snapshot
- Colgate-Palmolive operates a diversified portfolio of consumer goods spanning oral hygiene products (toothpastes, toothbrushes, mouthwashes), personal care items (soaps, shower gels, shampoos, conditioners), and pet nutrition offerings, generating revenue across its Oral, Personal, and Home Care divisions and Pet Nutrition segment.
- The company generates revenue through the production, marketing, and global distribution of branded consumer products to retail channels, leveraging established brand recognition and extensive distribution networks to maintain market share across multiple consumer categories.
- Colgate-Palmolive serves mass-market consumers globally, with primary customers including retail chains, supermarkets, and e-commerce platforms that distribute its products to households and individual consumers across developed and emerging markets.
Colgate-Palmolive is a multinational consumer goods manufacturer with a market capitalization of $74.6 billion and TTM revenue of $21.0 billion, positioning it as a significant player in the household and personal products sector. The company maintains competitive advantages through its portfolio of globally recognized brands, established distribution infrastructure, and diversified product offerings across oral care, personal care, and pet nutrition categories. With 33,600 employees and operations spanning multiple geographic regions, Colgate-Palmolive leverages scale and brand equity to sustain market leadership in the consumer defensive sector.
What this transaction means for investors
Simply put, investors shouldn’t fret over this sale. The transaction by Director Cahill was part of a prearranged option exercise and sale that doesn’t indicate any market timing or judgment regarding Colgate Palmolive stock.
As for the blue chip dividend-paying business itself, Colgate-Palmolive remains one of the most recognizable steady-Eddie investments out there. Currently trading at 19 times free cash flow, CL stock is slightly cheaper than normal, but is more of an income-generating investment at this point in its business life cycle. Paying a 2.3% dividend yield and having raised its payments for 62 straight years, Colgate’s returns to shareholders and defensive consumer-goods positioning make it a perfect cornerstone for investors focused on safety.
That said, over the last five years, Colgate’s organic sales, free cash flow, and dividend have only increased by 6%, 5%, and 2% annually, so investors shouldn’t expect market-smashing returns. In its last quarter, sales and EPS both rose by 5%, while it maintained its No. 1 and No. 2 positions across its myriad products and verticals. Ultimately, Colgate Palmolive is a top-tier holding for stability, but one I’m not particularly interested in as I’d rather have steadier growth options.
Should you buy stock in Colgate-Palmolive right now?
Before you buy stock in Colgate-Palmolive, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Colgate-Palmolive wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $399,832!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,374,595!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 9, 2026.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Colgate-Palmolive. The Motley Fool has a disclosure policy.
Recommended Articles
